PhotoniCare gets quality standard certification
PhotoniCare, maker of the OtoSight Middle Ear Scope, announces completion of their ISO 13485:2016 certification.
PhotoniCare, creator of the OtoSight Middle Ear Scope, which allows practitioners to noninvasively visualize through the eardrum to directly assess middle ear fluid, has just announced completion of their ISO 13485:2016 certification. This internationally recognized quality standard specifies the requirements for a quality management system in order to provide the highest level of devices and related services to patients and customers. The Quality Management System PhotoniCare, which services the company's OtoSight MIddle Ear Scope, has been found to meet all requirements of this prestigious certification.
"PhotoniCare's Otosight Middle Ear Scope uses optical coherence tomography to facilitate the diagnosis of acute otitis media," noted Andrew J. Schuman, MD, clinical assistant professor of pediatrics, Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire, and a member of the Editorial Advisory Board of Contemporary Pediatrics®. "Numerous studies have validated its use. Now that the company has achieved this certification, further reassuring providers that the device is worth integrating into a routine practice."
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Study finds reduced CIN3+ risk from early HPV vaccination
April 17th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
